A myriad of AI, science, and technology experts explore the real challenges and enormous opportunities facing entrepreneurs who are building the future of health. Raising Health, a podcast by a16z Bio + Health and hosted by Kris Tatiossian and Olivia Webb, dives deep into the heart of biotechnology and healthcare innovation. Join veteran company builders, operators, and investors Vijay Pande, Julie Yoo, Vineeta Agarwala, and Jorge Conde, along with distinguished guests like Mark Cuban, Greg ...
…
continue reading
المحتوى المقدم من Jon Chee. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Jon Chee أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Player FM - تطبيق بودكاست
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
🧬 David Li - Meliora Therapeutics - Part 4 | Mechanism Identification in Biotech | AI & ML in Drug Development | Creating a New Method for Drug Discovery | Fundraising for Meliora | Building a Foundational Startup Team
MP3•منزل الحلقة
Manage episode 428387618 series 3461709
المحتوى المقدم من Jon Chee. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Jon Chee أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
As a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code “TBSP” on https://www.excedr.com/rewards.
Part 4 of 4.
My guest for this week’s episode is David Li, CEO and co-founder of Meliora Therapeutics. Meliora's goal is to develop life-saving cancer therapies using cutting-edge science and machine learning. The company derives a comprehensive picture of how drugs interact with cancer biology by combining biofunctional readouts from numerous modalities using advanced machine learning and other computational techniques.
Before Meliora, David was Chief Business Officer at Everest Detection, an early detection liquid biopsy startup, and led commercial operations at Benchling, a life sciences software platform valued at $6 billion with over $500 million in funding.
David started his career in Goldman Sachs Healthcare Investment Banking Group and KKR's Private Equity Group, advising and investing in transactions exceeding $10 billion. His diverse financial and life sciences background offers valuable insights for founders.
Join us this week and hear about:
- David’s transition from private equity to co-founding Meliora and using AI/ML in drug development
- His fundraising experiences for Meliora and current outlook on the fundraising landscape in 2024
- His advice for aspiring entrepreneurs and reflections on “thinking big” in biotech
- Identifying mischaracterized mechanisms of action and establishing Meliora as a drug development company and computational platform
Please enjoy my conversation with David Li.
Timestamps:
00:28 Intro
02:00 Jason Scheltzer identifies mechanisms of action, the beginnings of Meliora
05:08 David meets Jason Scheltzer, forming Meliora with a thesis, as David becomes founding CEO and initial fundraising begins
07:20 David’s serendipitous meeting with Jason, getting on board as more than an investor
09:16 Building the early founding team at Meliora, establishing Meliora as a drug company
12:05 How Meliora is disrupting the status quo in drug discovery and development
17:24 David’s approach to building an internal pipeline and BD partnerships
19:49 David’s experience fundraising and his outlook on fundraising in 2024
22:21 Meloria’s 2-year vision, transitioning from Seed to Series A
24:03 Shoutouts and advice to 21-year old self
26:23 Outro
Find Our Guest, David Li, at these links:
Find Our Host, Jon Chee, at these links:
Social & Website
LinkedIn: https://www.linkedin.com/company/excedr/
Youtube: https://www.youtube.com/@excedr
Instagram: https://www.instagram.com/excedr_inc
Twitter: https://twitter.com/ExcedrInc
Facebook: https://www.facebook.com/excedr
TikTok: https://www.tiktok.com/@excedr
Podcast Website: https://www.thebiotechstartupspodcast.com/
Enriched Notes:
Topics Mentioned:
Benchling https://www.benchling.com/
Meliora Therapeutics https://www.melioratherapeutics.com/
Everest Detection https://everestdetection.com/
AstraZeneca https://www.astrazeneca.com/
Tagrisso https://www.tagrisso.com/
Drug candidates that were mischaracterized https://ergobio.substack.com/p/meliora-therapeutics-is-building
Series A, B, & C Rounds https://www.excedr.com/resources/series-funding-explained
Biotech Fundraising https://www.excedr.com/resources/biotech-startup-funding-options
Computational Platforms in Biotech https://www.nfx.com/post/bioplatforms-computational-biology
People Mentioned:
Jason Sheltzer https://www.linkedin.com/in/jason-sheltzer-ba0086234/
Joan Smith https://www.linkedin.com/in/joanclarasmith/
Claudio Chuaqui https://www.linkedin.com/in/claudio-chuaqui-5612381/
Andrew Coopersmith https://www.linkedin.com/in/andrew-s-coopersmith/
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
88 حلقات
MP3•منزل الحلقة
Manage episode 428387618 series 3461709
المحتوى المقدم من Jon Chee. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Jon Chee أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
As a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code “TBSP” on https://www.excedr.com/rewards.
Part 4 of 4.
My guest for this week’s episode is David Li, CEO and co-founder of Meliora Therapeutics. Meliora's goal is to develop life-saving cancer therapies using cutting-edge science and machine learning. The company derives a comprehensive picture of how drugs interact with cancer biology by combining biofunctional readouts from numerous modalities using advanced machine learning and other computational techniques.
Before Meliora, David was Chief Business Officer at Everest Detection, an early detection liquid biopsy startup, and led commercial operations at Benchling, a life sciences software platform valued at $6 billion with over $500 million in funding.
David started his career in Goldman Sachs Healthcare Investment Banking Group and KKR's Private Equity Group, advising and investing in transactions exceeding $10 billion. His diverse financial and life sciences background offers valuable insights for founders.
Join us this week and hear about:
- David’s transition from private equity to co-founding Meliora and using AI/ML in drug development
- His fundraising experiences for Meliora and current outlook on the fundraising landscape in 2024
- His advice for aspiring entrepreneurs and reflections on “thinking big” in biotech
- Identifying mischaracterized mechanisms of action and establishing Meliora as a drug development company and computational platform
Please enjoy my conversation with David Li.
Timestamps:
00:28 Intro
02:00 Jason Scheltzer identifies mechanisms of action, the beginnings of Meliora
05:08 David meets Jason Scheltzer, forming Meliora with a thesis, as David becomes founding CEO and initial fundraising begins
07:20 David’s serendipitous meeting with Jason, getting on board as more than an investor
09:16 Building the early founding team at Meliora, establishing Meliora as a drug company
12:05 How Meliora is disrupting the status quo in drug discovery and development
17:24 David’s approach to building an internal pipeline and BD partnerships
19:49 David’s experience fundraising and his outlook on fundraising in 2024
22:21 Meloria’s 2-year vision, transitioning from Seed to Series A
24:03 Shoutouts and advice to 21-year old self
26:23 Outro
Find Our Guest, David Li, at these links:
Find Our Host, Jon Chee, at these links:
Social & Website
LinkedIn: https://www.linkedin.com/company/excedr/
Youtube: https://www.youtube.com/@excedr
Instagram: https://www.instagram.com/excedr_inc
Twitter: https://twitter.com/ExcedrInc
Facebook: https://www.facebook.com/excedr
TikTok: https://www.tiktok.com/@excedr
Podcast Website: https://www.thebiotechstartupspodcast.com/
Enriched Notes:
Topics Mentioned:
Benchling https://www.benchling.com/
Meliora Therapeutics https://www.melioratherapeutics.com/
Everest Detection https://everestdetection.com/
AstraZeneca https://www.astrazeneca.com/
Tagrisso https://www.tagrisso.com/
Drug candidates that were mischaracterized https://ergobio.substack.com/p/meliora-therapeutics-is-building
Series A, B, & C Rounds https://www.excedr.com/resources/series-funding-explained
Biotech Fundraising https://www.excedr.com/resources/biotech-startup-funding-options
Computational Platforms in Biotech https://www.nfx.com/post/bioplatforms-computational-biology
People Mentioned:
Jason Sheltzer https://www.linkedin.com/in/jason-sheltzer-ba0086234/
Joan Smith https://www.linkedin.com/in/joanclarasmith/
Claudio Chuaqui https://www.linkedin.com/in/claudio-chuaqui-5612381/
Andrew Coopersmith https://www.linkedin.com/in/andrew-s-coopersmith/
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
88 حلقات
Todos os episódios
×مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.